The research, led by Lubin Gou and Junqiang Lei of the First Hospital of Lanzhou University and Lanzhou University’s First Clinical Medical College, focused on patients with liver cirrhosis without overt hepatic encephalopathy, a stage abbreviated LC-nOHE. This is the window in which the disease has already compromised liver function but has not yet produced the confusion, disorientation, and personality changes that define overt hepatic encephalopathy. Understanding what happens in the brain during this silent phase is critical, because it may reveal the earliest opportunities for intervention before irreversible damage takes hold.

The team recruited 86 patients with liver cirrhosis but no overt encephalopathy, along with 62 healthy controls, and acquired high-resolution three-dimensional T1-weighted magnetic resonance images of every participant’s brain. From these scans, the researchers extracted the volume of the thalamus and three distinct measures of cortical shape: cortical thickness, sulcal depth, and fractal dimension, a measure of the complexity of the brain’s folded surface. Rather than examining these features in isolation, the investigators constructed structural covariance networks, mathematical maps in which brain regions are connected if their anatomical features covary across individuals. Such networks are widely used as proxies for coordinated maturational and degenerative processes, offering a window into how brain regions change together as a system.

The results were striking at multiple levels. Compared with healthy controls, patients with cirrhosis showed enlargement of the thalamus alongside a broad range of cortical morphological abnormalities. At the level of whole-network organization, the thalamo-cortical structural covariance networks of patients displayed reduced segregation, meaning the brain’s specialized modules were less clearly differentiated, and decreased integration, meaning efficient communication across the network was impaired. These two properties, segregation and integration, are hallmarks of a healthy, well-organized brain, and their simultaneous deterioration suggests a fundamental disruption of the architecture that supports cognition.

Zooming in on individual network nodes, the researchers found that the centrality of three regions was significantly reduced in patients: the thalamus itself, the supramarginal gyrus, and the insula. Each of these regions plays a recognizable role in the syndrome. The thalamus relays sensory and motor signals to the cortex and regulates consciousness and alertness; the supramarginal gyrus contributes to language and spatial cognition; and the insula supports interoception and awareness of the body’s internal state. Reduced centrality in these hubs indicates that they had lost influence within the network, becoming less connected to the rest of the brain’s structural architecture.

Perhaps the most clinically significant finding was the relationship between brain changes and liver function. The degree centrality of the thalamus was negatively correlated with liver function measures, meaning that the worse the liver was performing, the more the thalamus had lost its position within the brain’s structural network. This correlation ties the brain imaging directly to the severity of liver disease and supports the idea that the thalamus sits at the front line of the liver-brain axis, the pathway by which hepatic dysfunction, circulating toxins such as ammonia, and systemic inflammation are translated into neural injury.

To move beyond correlation and probe causality, the team applied a technique called causal analysis of structural covariance networks, or CaSCN. This approach examines how changes in one brain region’s morphology relate to changes in others across the progression of disease, allowing researchers to ask which region leads and which follows. The analyses demonstrated that thalamus volume had causal effects on the alterations of cortical morphology as liver dysfunction progressed. In other words, the data are consistent with a model in which the thalamus is not merely another victim of cirrhosis but an active driver, propagating structural changes outward to the cortical regions with which it is connected.

The study then took an unusual additional step: linking the brain imaging to genomics through imaging transcriptomics. Using normative gene-expression profiles from the Allen Human Brain Atlas, the researchers evaluated whether the spatial pattern of causal effects across the cortex overlapped with the spatial distribution of specific genes. It did. The pattern of causal path coefficients was spatially correlated with the expression of particular genes in the normative atlas, suggesting that the cortical regions most vulnerable to thalamus-driven change are also those with distinctive molecular signatures. Gene ontology analyses pointed toward enrichment in biological processes, molecular functions, and cellular components that may help explain why some cortical areas are preferentially affected while others are relatively spared.

Taken together, the findings provide a comprehensive, multilevel view of how the thalamo-cortical circuit becomes progressively vulnerable in liver cirrhosis before overt encephalopathy appears. The enlargement of the thalamus, consistent with processes such as edema or glial changes reported in prior literature on hepatic encephalopathy, appears to initiate a cascade that erodes the segregation and integration of the entire structural network, strips key hubs of their centrality, and reshapes the cortex in patterns governed partly by underlying gene expression. Because the thalamus’s network position tracks liver function, measures of thalamo-cortical network integrity could potentially serve as imaging biomarkers for identifying patients at risk of progressing to overt hepatic encephalopathy, enabling earlier monitoring and treatment.

The authors emphasize that these findings offer a potential mechanism-driven framework for understanding the earliest brain consequences of liver disease, one that connects organ function, network neuroscience, and transcriptomics within a single analytical pipeline. The work was supported by the Lanzhou University First Affiliated Hospital Foundation and the Science and Technology Department of Gansu Province, and it was approved by the Institutional Ethics Committee of the First Hospital of Lanzhou University. As cirrhosis continues to affect millions worldwide, studies like this one bring clinicians closer to detecting, and perhaps preventing, the neurological toll of liver disease before it announces itself in the clinic.

Subject of Research: Structural covariance network alterations of the thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy

Article Title: Multilevel structural covariance network alterations of thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy: associations with liver function and imaging transcriptomics

Article References: Gou, L., Ren, H., Xu, W., Gao, Y., Wang, S., Zhang, Y., Dou, Y., & Lei, J. (2026). Multilevel structural covariance network alterations of thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy: associations with liver function and imaging transcriptomics. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02790-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02790-6

Keywords: liver cirrhosis, hepatic encephalopathy, thalamus, thalamo-cortical circuit, structural covariance network, MRI, liver-brain axis, imaging transcriptomics, cortical thickness, liver function, neuroimaging, Allen Human Brain Atlas

The study, led by Hélène Rostand and Aurélie Kas of the Department of Nuclear Medicine at Pitié-Salpêtrière Hospital in Paris, together with collaborators from reference centres for paraneoplastic neurological syndromes across France, took a deliberately pragmatic approach. Rather than enrolling a carefully curated cohort of textbook cases, the team examined every consecutive patient referred for brain [¹⁸F]-FDG PET/CT with suspected autoimmune encephalitis between January 2020 and July 2023. This real-world design matters enormously, because the true value of any diagnostic test lies not in how it performs on idealised patients but in how it performs in the messy, ambiguous setting of a working hospital. A total of 141 patients, with a mean age of 48 years and a wide age range spanning young adults to the very elderly, were retrospectively included in the analysis.

Establishing a definitive diagnosis for each patient was a rigorous process. Final diagnoses were assigned using international diagnostic criteria for autoimmune encephalitis, combined with expert consensus and careful clinical follow-up, ensuring that the PET findings could be judged against a trustworthy gold standard rather than circular reasoning. The results of this adjudication were sobering in themselves: only 33 percent of the patients ultimately had autoimmune encephalitis, 43 percent turned out to have alternative differential diagnoses, and 24 percent remained undetermined even after comprehensive work-up. Among the encephalitis cases, 70 percent met criteria for definite disease, 63 percent were seropositive for a neural antibody, and only 35 percent had supportive findings on magnetic resonance imaging. These figures starkly illustrate the diagnostic gap that clinicians face: a substantial majority of patients scanned for suspected encephalitis do not have it, and even among those who do, both antibody testing and MRI frequently fail to confirm the diagnosis.

The biological rationale behind using [¹⁸F]-FDG PET in this context rests on decades of neuroscience. The radiotracer [¹⁸F]-fluoro-2-deoxy-D-glucose is taken up by metabolically active cells in proportion to their glucose consumption, and since the brain’s enormous energy demand is dominated by synaptic activity, the PET signal serves as a proxy for regional neuronal and glial function. Foundational work in the late 1970s validated the tomographic measurement of local cerebral glucose metabolic rate in humans, and more recent research has shown that the FDG signal is in fact strongly driven by astroglial glutamate transport, linking the image directly to synaptic chemistry. In inflammatory brain disease, this translates into a characteristic interplay of hypometabolism, reflecting neuronal dysfunction in damaged tissue, and hypermetabolism, which may reflect active inflammatory processes, seizure activity or compensatory network changes.

When the researchers compared the 46 patients with autoimmune encephalitis to 54 healthy controls using voxel-wise and regional analyses, a distinctive metabolic signature emerged with striking consistency. The encephalitis patients showed widespread cortical hypometabolism accompanied by hypermetabolism in a set of deep and medial structures: the mesiotemporal lobe, encompassing the hippocampus and adjacent limbic cortex, the basal ganglia, the cerebellum, the midbrain and the insula. This pattern of simultaneous cortical depression and limbic-plus-extralimbic activation fits neatly with what is known about the pathophysiology of antibody-mediated encephalitis, in which limbic structures are preferentially targeted by autoantibodies against synaptic proteins, while motor and subcortical circuits are frequently engaged. Earlier studies in anti-NMDA receptor and anti-LGI1 encephalitis had hinted at exactly this combination, but the present study confirms it in a consecutive, unselected cohort that includes both seropositive and seronegative disease.

The most clinically consequential finding, however, came from the head-to-head comparison between confirmed autoimmune encephalitis and the patients with differential diagnoses. The two groups differed profoundly: encephalitis patients exhibited lower metabolism in occipital and prefrontal cortical regions but higher metabolism in the mesiotemporal lobe, the insula and the midbrain, with differences reaching high statistical significance. When these regional metabolic measures were tested for their ability to discriminate between the two conditions, the combination yielded an area under the receiver operating characteristic curve of 0.82 to 0.83, indicating good discriminative power in a setting where misdiagnosis carries severe consequences. Mesiotemporal hypermetabolism, whether observed alone or in combination with cortical hypometabolism, proved to be the single most specific feature of the disease. By contrast, several other regional metrics and metabolic ratios that had been proposed in earlier literature, including cortex-to-striatum ratios, performed less reliably in this cohort, with areas under the curve at or below 0.73, a finding that will temper expectations for simpler quantitative shortcuts.

Importantly, the team also evaluated the simplest possible use of the technology: visual reading of the PET images by an experienced nuclear physician, without quantitative post-processing. Here the results revealed a crucial dependence on age. In patients under 40 years, visual analysis achieved positive and negative predictive values of 82 percent and 81 percent respectively, meaning that a positive scan was very likely to indicate true encephalitis and a negative scan reasonably reassuring. In the 40-to-65-year age band, predictive values slipped to 81 percent and 69 percent, and in patients over 65 they fell further to 79 percent and 64 percent. The explanation is almost certainly the age-related confounding of brain glucose metabolism, since normal ageing, prodromal neurodegenerative disease and cerebrovascular pathology all alter the metabolic landscape of older brains, blurring the contrast between diseased and healthy tissue. The practical implication is that the test is most decisive in younger patients, precisely the population in which autoimmune encephalitis is most common and most frequently mistaken for a primary psychiatric disorder.

The stakes of this diagnostic uncertainty are difficult to overstate. Autoimmune encephalitis responds to immunotherapy, and early treatment is strongly associated with better neurological outcomes, whereas the conditions that mimic it, including viral encephalitis requiring antivirals, tumours requiring oncological management, and degenerative dementias requiring supportive care, demand entirely different and sometimes mutually incompatible interventions. Studies of misdiagnosis in adults have shown that a substantial fraction of patients labelled with autoimmune encephalitis actually suffer from other diseases, exposing them to unnecessary immunosuppression while the true illness progresses. Conversely, patients with genuine encephalitis who are seronegative or antibody-negative, a situation that applies to more than a third of cases in this cohort, may be denied timely immunotherapy because the laboratory confirmation never arrives. A metabolic biomarker that works regardless of antibody status, and that can flag disease even when MRI is normal, addresses precisely this vulnerable gap.

The study also strengthens the growing role of FDG PET as a longitudinal tool in this disease. Prior work has demonstrated that serial FDG PET can track the response to immunotherapy and that changes in brain metabolism over time carry prognostic weight, with recovery of cortical metabolism heralding clinical improvement. By establishing robust discriminative thresholds in a real-world population, the new findings give clinicians a firmer foundation not only for initial diagnosis but also for interpreting follow-up scans. The authors’ commitment to reproducibility deserves note: the entire image-processing pipeline, including the voxel-wise and regional analyses stratified by age and treatment status, has been released as a unified, publicly accessible workflow on GitHub, allowing other centres to adopt the methodology directly rather than reconstructing it from the methods section alone. The underlying datasets are available from the corresponding author on reasonable request.

Taken together, the study positions brain [¹⁸F]-FDG PET/CT as a genuinely complementary diagnostic biomarker for autoimmune encephalitis, one that neither replaces antibody testing and MRI nor competes with clinical judgement, but that adds an independent, physiologically grounded layer of evidence in the diagnostically critical early window. Its characteristic signature, cortical hypometabolism paired with mesiotemporal, insular and midbrain hypermetabolism, is now validated against the full spectrum of real-world mimics rather than healthy volunteers alone, which is what makes the high discriminative performance meaningful for daily practice. With diagnostic delays in autoimmune encephalitis still measured in weeks and treatment response closely tied to how quickly immunotherapy begins, the message from this Parisian cohort is clear: in the right patient, particularly the young patient with an unexplained encephalopathic or psychiatric syndrome, a metabolic scan of the brain may be the fastest route to the right diagnosis and, ultimately, the right treatment.

The study, led by Yuhui Sha and Jun Ni, together with collaborators including Joanna M. Wardlaw of the University of Edinburgh, set out to systematically characterize symptomatic diffusion-weighted imaging lesions, known as sDWI lesions, and incidental DWI lesions, known as iDWI lesions, in patients with probable CAA. Diffusion-weighted imaging is an MRI sequence exquisitely sensitive to acute cellular injury: when blood flow to brain tissue fails and cells begin to swell with cytotoxic edema, water molecules lose their freedom to diffuse, and the affected region lights up brightly on the scan. In CAA, these bright spots have been the subject of a running debate. Autopsy work from previous groups, including studies by Ter Telgte and colleagues, has suggested that DWI-positive lesions in CAA correspond histologically to microinfarcts, confirming that they represent genuine ischemia rather than hemorrhage or artifact. Yet the clinical relevance, prevalence, and mechanisms of these lesions remained contested.

To resolve the question, the team drew on a prospective cohort of cerebral small vessel disease patients recruited at Peking Union Medical College Hospital between March 2017 and February 2026. Using the Boston criteria version 1.5, the standard clinicoradiological framework for diagnosing CAA without tissue biopsy, they enrolled 185 patients with probable CAA. Each participant underwent detailed baseline clinical assessment and multimodal MRI, including imaging markers of small vessel disease such as lacunes, cerebral microbleeds, and cortical superficial siderosis, the latter being a sign of chronic blood leaking over the surface of the brain. Ninety-nine of the patients returned for follow-up MRI, generating 163 scans in total, which allowed the researchers to estimate not only cross-sectional prevalence but also cumulative incidence over time.

The results were revealing in two directions. First, ischemia turned out to be anything but rare. Symptomatic DWI lesions were detected in 29 patients, while incidental DWI lesions, discovered on scans performed for other reasons, appeared in 49 patients, more than a quarter of the entire cohort. Kaplan–Meier analysis of the followed subgroup showed that over three years, the cumulative incidence of new symptomatic DWI lesions was 9.45 percent, with a 95 percent confidence interval of 0.67 to 17.46 percent, while the cumulative incidence of incidental lesions was considerably higher at 25.74 percent, with a confidence interval spanning 15.2 to 34.97 percent. In other words, roughly one in four CAA patients followed longitudinally was destined to develop a small ischemic lesion within three years, most of them without any clinical fanfare.

Second, and perhaps more striking, the two lesion types behaved like two different diseases. When the researchers constructed lesion probability maps to visualize topography, symptomatic DWI lesions clustered predominantly in deep brain regions, accounting for 72.7 percent of their locations. Incidental lesions, by contrast, were mainly found in cortical and juxtacortical regions, the ribbon of gray matter and the immediately underlying white matter, in 62.5 percent of cases. This anatomical split is not trivial. Deep and superficial cerebral territories are supplied by different vascular trees, with deep perforating arterioles and leptomeningeal cortical vessels subject to different hemodynamic stresses and pathological processes. A preferential distribution suggests a preferential mechanism.

That suspicion was confirmed by prospective Cox regression analysis, which adjusted for age and sex and, for the incidental lesions, also for traditional vascular risk factors and focal superficial siderosis. For symptomatic DWI lesions, the independent predictors were the number of traditional vascular risk factors, including hypertension, diabetes mellitus, coronary artery disease, and smoking, with a hazard ratio of 2.968 per additional risk factor, and the presence of lacunes, small old infarcts typical of hypertensive arteriopathy, with a hazard ratio of 1.187. Both reached conventional statistical significance, with P values of 0.013 and 0.016 respectively. This profile points toward the familiar machinery of atherosclerotic and hypertensive small vessel disease, superimposed on the amyloid-laden vasculature of CAA patients.

Incidental DWI lesions told a different story. Their independent predictors were lacunes, with a hazard ratio of 1.158, disseminated cortical superficial siderosis, with a hazard ratio of 2.994, and lobar cerebral microbleed grade, with a hazard ratio of 2.059. Notably, traditional vascular risk factors did not independently predict these silent lesions once adjustments were made. Disseminated siderosis and a heavy burden of lobar microbleeds are both hallmarks of advanced amyloid pathology, marking vessels that leak blood products into the subarachnoid space and brain parenchyma. Their association with cortical and juxtacortical ischemic lesions fits a mechanistic picture in which amyloid-laden leptomeningeal and cortical vessels, damaged by both amyloid deposition and hemosiderin-related injury, suffer episodic failure of perfusion, producing tiny cortical microinfarcts that the patient never notices.

The implications ripple outward in several directions. Clinically, the findings suggest that when a CAA patient presents with an acute neurological event, a DWI-positive lesion in deep structures is likely to be associated with conventional vascular risk factors and may warrant aggressive management of those factors. Conversely, incidental cortical lesions in a patient with disseminated siderosis may signal active amyloid-related vascular injury, which has been linked in prior work to increased risks of both future hemorrhage and cognitive decline. Earlier studies have shown that silent ischemic infarcts are associated with hemorrhage burden in CAA, and that DWI lesions after intracerebral hemorrhage predict recurrent stroke, so the new prospective risk factor data give clinicians a sharper tool for risk stratification.

Scientifically, the study reframes DWI-positive lesions as a dynamic window on small vessel disease activity. Traditional imaging markers such as microbleeds and siderosis are cumulative, recording injury that may have accumulated over years. DWI lesions, by contrast, are acute, appearing and resolving within days to weeks, and their signal characteristics evolve in a characteristic sequence as microinfarcts mature. Their detection rate in a longitudinal cohort therefore reflects ongoing disease activity, in the same way that incident troponin release reflects active myocardial injury. The authors propose that DWI-positive lesions could serve as a useful imaging marker of SVD activity and injury in future longitudinal studies and clinical trials of CAA. This matters because the CAA therapeutic pipeline is, for the first time, showing real signs of life. Immunotherapy trials with anti-amyloid antibodies such as ponezumab have been conducted, and a Phase 2 study of the RNA interference therapeutic ALN-APP, designed to reduce production of amyloid precursor protein, is currently recruiting patients with CAA. Trials like these need sensitive, quantifiable markers of target engagement and disease progression, and DWI lesion rates could fill that role.

There are, as always, caveats. The cohort of 185 patients, and the 99 with follow-up imaging, is modest by the standards of national registry studies, and the confidence interval around the three-year incidence of symptomatic lesions is wide, reflecting the relative rarity of these events. Probable CAA by Boston criteria is not histologically confirmed disease, although the criteria perform well in autopsy-validated settings. The observational design cannot definitively separate correlation from causation: lacunes may predict DWI lesions because they share upstream causes rather than because old infarcts directly provoke new ones. And MRI at typical clinical field strengths can miss very small cortical microinfarcts, meaning the true incidence of ischemia in CAA may be even higher than these figures suggest. Nevertheless, the consistency of the topographical and risk factor dissociation across analyses lends credibility to the central conclusion.

The broader message is a conceptual one. CAA, the study concludes, is not simply a hemorrhagic disease with an occasional ischemic afterthought. Cerebral ischemia is common, mechanistically patterned, and readable on standard clinical MRI. Symptomatic deep lesions track the burden of systemic vascular risk, while silent cortical lesions track the severity of amyloid vasculopathy itself, a dissociation that echoes recent work in CAA and CADASIL cohorts showing high prevalences of incidental DWI lesions with distinct clinical associations. For a disease whose diagnosis has historically hinged on documenting bleeding, the growing recognition that acute ischemic lesions can be counted, mapped, and followed over time offers both a warning and an opportunity: the amyloid-diseased vessel fails in more ways than one, and each failure mode now has its own signature that clinicians and trialists can learn to read.

Takayasu arteritis, often called “pulseless disease,” primarily affects the aorta and its major branches. Inflammation can thicken the arterial wall, reduce the diameter of the vessel, and eventually restrict blood flow to the brain, arms, kidneys, or other organs. Neurological complications may include transient ischemic attacks, strokes, dizziness, visual disturbances, and fainting. Because symptoms and laboratory markers do not always reflect the full extent of vascular injury, clinicians increasingly rely on imaging to identify active inflammation and structural narrowing. The new work explores an unusual imaging target: the amygdala, a small almond-shaped structure located in the medial temporal lobe and involved in emotional processing, stress responses, autonomic regulation, and communication with the immune system.

The investigators analyzed data from 303 people with Takayasu arteritis who underwent whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography, commonly known as ¹⁸F-FDG PET/CT. The radioactive glucose analogue is taken up by metabolically active cells, allowing PET to visualize tissues with increased glucose consumption. In large-vessel vasculitis, inflammatory cells in the arterial wall can accumulate FDG and produce a measurable signal. The researchers also quantified FDG uptake in the amygdala and bone marrow, as well as in affected vessel walls, while collecting clinical information, blood-test results, and vascular imaging findings. Participants were followed for a median of 27 months, during which cerebrovascular and other adverse events were recorded.

The principal result was not uniform across the entire cohort. When all participants were analyzed together, amygdalar standardized uptake values, or SUVs, were not significantly associated with cerebrovascular events. SUV is a semi-quantitative measure that estimates how much tracer has accumulated in a region after accounting for factors such as injected dose and body size. SUVmax represents the highest measured activity within a region of interest, whereas SUVmean reflects the average activity. This distinction matters because a single intense voxel can influence SUVmax, while SUVmean may provide a broader estimate of regional metabolic activity. In the overall study population, neither measurement consistently separated patients who experienced cerebrovascular events from those who remained event-free.

A clearer pattern emerged in the treatment-naïve subgroup. Patients who had suffered cerebrovascular events showed lower amygdalar activity than those without such events. Mean amygdalar SUVmax was 9.3 compared with 10.3 in event-free patients, while mean SUVmean was 6.6 compared with 7.4. The differences were statistically significant, with p values of 0.011 and 0.003, respectively. When the researchers divided patients according to amygdalar metabolic activity, 24.3 percent of people in the low-SUV group had experienced cerebrovascular events, compared with 15.9 percent in the higher-SUV group. The low-activity group also had higher immunoglobulin G and immunoglobulin A levels and lower lymphocyte counts, suggesting that reduced amygdalar uptake may coexist with distinctive systemic immune features.

The relationship became especially notable when the researchers examined structural disease in the arteries supplying the head and neck. Higher amygdalar SUVmax was identified as an independent protective factor against combined carotid and vertebral artery stenosis. The reported odds ratio was 0.876, with a p value of 0.032. An odds ratio below one indicates that, within the statistical model, increasing amygdalar activity was associated with lower odds of the outcome after accounting for other evaluated factors. The carotid arteries deliver blood to much of the brain’s anterior circulation, while the vertebral arteries contribute to the posterior circulation. Narrowing in both systems can substantially reduce cerebral blood flow and increase the risk of ischemic injury.

Follow-up findings provided additional support for the signal, although they also illustrated the complexity of the biology. Patients who later experienced cerebrovascular events had a significantly lower amygdalar SUVmax than a group described as having new-onset symptoms without the same event outcome: 8.2 compared with 10.4. This observation raises the possibility that amygdalar metabolic activity could reflect a brain-body state associated with vascular vulnerability before or during clinically important disease. However, PET uptake is not a direct measurement of stress, emotion, or immune control. It can be influenced by age, medication, glucose levels, scanner characteristics, image-processing methods, brain structure, and other medical conditions. The amygdala is also small, making accurate measurement vulnerable to partial-volume effects, in which limited spatial resolution causes activity from neighboring tissues to blend into the region of interest.

The authors’ interpretation builds on a growing body of research concerning the brain’s role in cardiovascular and immune regulation. Earlier studies in other populations have linked resting amygdalar activity with cardiovascular events, while experimental work has shown that stress-related neural circuits can influence the hypothalamic-pituitary-adrenal axis, sympathetic nervous system, bone marrow activity, and inflammatory signaling. The amygdala communicates with regions that regulate autonomic output and endocrine responses, and these pathways can affect circulating immune cells and the behavior of inflammatory tissues. In Takayasu arteritis, such neuroimmune interactions could theoretically alter the inflammatory environment surrounding the aorta and its branches. The present study does not prove this mechanism, but it adds a new imaging-based association to the emerging concept that vascular inflammation may be shaped by both immune processes and neural activity.

The findings should therefore be viewed as a potential biomarker discovery rather than a clinical test ready for routine use. The study was observational, and its results cannot establish whether reduced amygdalar activity contributes to arterial stenosis, results from chronic vascular disease, or reflects another factor shared by patients with worse outcomes. The absence of a significant association in the full cohort also suggests that treatment exposure and disease history may modify the relationship. In addition, the reported associations came from a single clinical cohort and require confirmation in independent populations using standardized PET acquisition and analysis. Future studies could combine serial brain PET, vascular imaging, inflammatory biomarkers, autonomic measurements, psychological assessments, and long-term clinical follow-up. If the association is reproduced, amygdalar metabolism might eventually help identify patients who need closer neurological surveillance, more detailed carotid and vertebral imaging, or intensified prevention strategies.

For now, the study offers a striking shift in perspective on Takayasu arteritis. The disease is traditionally assessed through arterial anatomy, blood-flow measurements, laboratory inflammation markers, and metabolic activity within the vessel wall. The new results suggest that the brain itself may contain information about the risk of vascular complications. A low amygdalar PET signal cannot yet predict an individual stroke, and it should not replace established clinical evaluation. Nevertheless, the work highlights how a scan originally used to map glucose metabolism can reveal connections between emotional-neural circuitry, systemic immunity, and arterial injury. As researchers continue to decode these pathways, the amygdala may become an important part of the story of how large-vessel inflammation affects the whole body.

Subject of Research: Takayasu arteritis, amygdalar metabolism, cerebrovascular events, and carotid-vertebral artery stenosis

Article Title: Amygdalar metabolic activity associated with cerebrovascular events and carotid-vertebral artery stenosis in takayasu arteritis

Article References: Ma L, Wu B, Wu S, et al. “Amygdalar metabolic activity associated with cerebrovascular events and carotid-vertebral artery stenosis in takayasu arteritis.” European Journal of Nuclear Medicine and Molecular Imaging (2026). References include Tawakol A, Ishai A, Takx RA, et al. “Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study.” The Lancet. 2017;389:834–845.

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08090-z

Keywords: Takayasu arteritis; amygdala; ¹⁸F-FDG PET/CT; cerebrovascular events; carotid artery stenosis; vertebral artery stenosis; neuroimmune interaction; vascular inflammation; brain metabolism; nuclear medicine imaging

The contrast is striking because cortical thinning is generally associated with normal aging and, when accelerated in specific areas, with neurodegenerative disease. The cerebral cortex is the brain’s folded outer layer, containing networks involved in memory, language, attention, decision-making and sensory processing. In Alzheimer’s disease, damage often emerges in a characteristic sequence that includes the entorhinal cortex, which serves as an important gateway for memory networks, followed by temporal and other cortical regions. In the new study, researchers focused on a composite measure encompassing the entorhinal, fusiform, inferior temporal and middle temporal cortices—areas known to be especially susceptible to Alzheimer’s-related changes.

The study combined data from two independent research groups that differed substantially in both age and sex. One group included 387 men from the Vietnam Era Twin Study of Aging, with an average age of about 62 years. The other consisted of 1,097 women participating in the Women’s Health Initiative Memory Study, whose average age was approximately 78. Using participants’ residential histories, the researchers estimated exposure to outdoor PM2.5 and NO2 during the three years preceding each person’s MRI scan. PM2.5 refers to airborne particles no larger than 2.5 micrometers in diameter—roughly one-thirtieth the width of a human hair. Because of their small size, these particles can penetrate deep into the lungs and may trigger systemic biological effects. Nitrogen dioxide is a reactive gas produced largely by fuel combustion, particularly from traffic and other urban sources.

Among the older women, higher exposure to both pollutants was associated with a thinner cortex across the Alzheimer’s-vulnerable regions. The researchers calculated that each additional microgram per cubic meter of PM2.5 exposure corresponded to an estimated cortical-thickness difference comparable to approximately 13 months of aging. For NO2, each additional part per billion was associated with a difference comparable to roughly three months of aging. These comparisons do not mean that pollution literally adds a fixed number of months to a person’s biological age, nor do they establish that exposure caused the tissue changes. Instead, they provide a way to express the size of the statistical association relative to typical age-related differences in cortical thickness.

The pollution signal was not limited to the four Alzheimer’s-related regions. In the older women, higher PM2.5 exposure was associated with a thinner cortex in 23 of the 34 brain regions examined, spanning the frontal, parietal, temporal and occipital lobes. Such a widespread pattern suggests that the effects of air pollution, if confirmed, may involve broad brain systems rather than a single memory circuit. Potential pathways include inflammation, oxidative stress, impaired blood-vessel function and disruption of the blood-brain barrier, a selective cellular interface that helps regulate which substances enter nervous tissue. Fine particles may also influence the brain indirectly through the lungs and bloodstream, although the present study did not measure the biological mechanisms responsible for the observed associations.

The younger men displayed a very different pattern. In this group, greater exposure to PM2.5 and NO2 was associated with a thicker cortex in the Alzheimer’s-vulnerable regions. While a thicker cortex is often interpreted as a sign of healthier brain tissue, that assumption is not always reliable. Some research suggests that cortical thickening can occur during early phases of certain disease processes, potentially reflecting inflammation, fluid-related swelling, enlargement of glial or neural cells, or other compensatory responses. Early pathological changes related to amyloid accumulation may also alter brain structure before later neurodegeneration produces measurable thinning. However, the study did not measure amyloid, tau, inflammation or other biomarkers, so none of these explanations can be confirmed.

An age-related analysis offered a possible clue to the divergent findings. Among the men, the positive association between PM2.5 exposure and cortical thickness gradually weakened between approximately ages 55 and 64 and became negative after around age 65. The later negative association was not statistically significant, meaning the evidence was insufficient to rule out the possibility that it resulted from chance. Even so, the trajectory raises the possibility that the brain’s structural response to pollution may change over the course of aging. A temporary thickening phase could represent an early biological reaction, followed by thinning as damage accumulates. This interpretation remains a hypothesis rather than a demonstrated sequence, because the participants were assessed at a single point in time rather than repeatedly over many years.

The researchers emphasize that the study cannot determine whether age, sex or other differences between the two groups explain the contrasting results. The participants came from separate cohorts with different demographic, health and life-history characteristics, and the analysis was observational. Residential pollution estimates also represent modeled exposure rather than direct personal measurements and may not capture time spent indoors, occupational exposure, indoor pollution, individual activity patterns or differences in pollutant composition. In addition, brain structure can be influenced by education, cardiovascular health, genetics, socioeconomic conditions, smoking, physical activity and many other factors. Statistical associations in MRI data therefore cannot be interpreted as proof that air pollution directly caused cortical injury or that the participants will develop Alzheimer’s disease.

Even with these limitations, the findings add to a growing body of research linking environmental exposures with brain aging and dementia-related biology. Air pollution is widespread, persistent and potentially modifiable through changes in transportation, energy production, urban planning and public-health policy. The study’s senior investigators argue that advanced neuroimaging can help identify possible effects of pollution years before dementia symptoms become visible. The next stage of research will require longitudinal studies that follow men and women from the same cohorts over time, repeatedly measure pollution exposure and brain structure, and include biomarkers for amyloid, tau, inflammation and vascular injury. Researchers will also need to track cognitive performance to determine whether pollution-related cortical changes predict memory decline or elevated Alzheimer’s risk. Until those studies are completed, the central message is one of caution: air pollution may leave a measurable imprint on the aging brain, but that imprint may not be uniform—and a thicker cortex at one stage of life may not necessarily signal better brain health.

Subject of Research: People

News Publication Date: 14-Jul-2026

Web References: https://ini.usc.edu/ ; https://keck.usc.edu/faculty-search/lauren-salminen/ ; https://doi.org/10.1016/j.neuro.2026.103495

References: NeuroToxicology, DOI: 10.1016/j.neuro.2026.103495

Image Credits: Stevens INI

Keywords: Air pollution, PM2.5, nitrogen dioxide, NO2, Alzheimer’s disease, cortical thickness, brain aging, neuroscience, environmental health, neurodegeneration

Neonatal encephalopathy, a condition characterized by disturbed neurological function in newborns, often stems from perinatal hypoxic-ischemic injury. Its unpredictable trajectory frequently leaves clinicians grappling with imprecise prognoses, making treatment decisions daunting. Standard MRI metrics, while invaluable, primarily provide averaged diffusion measurements that fail to capture the intricacies of brain tissue heterogeneity. Diffusion kurtosis imaging, by contrast, extends beyond these traditional limits by assessing the degree of non-Gaussian water diffusion, thus illuminating subtler microstructural alterations. These distinctions hold potential to unravel complex pathophysiological processes occurring in the vulnerable neonatal brain.

At the core of DKI’s promise lies its ability to quantify kurtosis parameters, which essentially describe the deviation of water diffusion from simple Gaussian behavior. This sensitivity to microenvironment complexity enables the detection of subtle changes in cellular organization, density, and integrity—particularly relevant in the context of neonatal brain injury characterized by heterogeneous involvement of gray and white matter. Importantly, this could permit earlier and more accurate identification of infants at risk for long-term neurodevelopmental impairments, potentially before conventional imaging signs become evident.

The study in question meticulously explores the application of DKI metrics in neonates with varying severities of encephalopathy, mapping diffusion kurtosis parameters across several brain regions integral to motor, sensory, and cognitive functions. By correlating these diffusion profiles with clinical outcomes, including neurodevelopmental milestones recorded months later, the research aims to establish robust biomarkers that transcend the temporal limitations of current evaluation paradigms. The results reveal a complex interplay between regional kurtosis abnormalities and clinical prognosis, highlighting both the promise and current boundaries of DKI.

One of the enlightening revelations from this research is how diffusion kurtosis measures in deep gray matter structures—such as the basal ganglia and thalamus—show remarkable correlation with motor outcome deficits. These regions are notoriously difficult to evaluate traditionally but are pivotal in neurodevelopmental prognostication. The study demonstrates that elevated kurtosis values, indicative of altered microstructural complexity, might reflect early cytotoxic edema or evolving gliosis, each bearing distinct clinical implications. This insight adds a layer of nuance that could ultimately guide therapeutic interventions more precisely.

However, while DKI introduces a groundbreaking dimension of microstructural insight, its integration into routine clinical practice faces significant obstacles. The complexity of acquisition protocols demands longer scan times, which is challenging in neonatal populations due to movement and physiological instability. Moreover, the computational algorithms required for kurtosis analysis necessitate advanced software and expertise not ubiquitously available in all neonatal neuroimaging units. These technical hurdles underscore a key limitation: without widespread technological and methodological standardization, the clinical applicability of DKI remains a hurdle.

In addition to technical challenges, biological interpretation of DKI parameters remains an evolving field demanding cautious scrutiny. Diffusion kurtosis reflects a convolution of multiple cellular phenomena, including changes in intracellular and extracellular compartments, myelination patterns, and axonal density variations. Disentangling which pathological processes correspond to specific kurtosis changes requires further correlative studies incorporating histopathology or additional biomarkers. Such insight is critical to avoid overinterpretation and to tailor clinical utility precisely.

This area of study also raises intriguing questions about the potential of DKI to monitor therapeutic responses. Hypothermia, the current standard of care for hypoxic-ischemic encephalopathy, has variable outcomes. The prospect that DKI could serve as a biomarker to assess ongoing brain microstructure during and after intervention opens exciting avenues for personalized medicine. Monitoring kurtosis changes longitudinally might reveal neuroplastic recovery or progressive injury, facilitating timely alterations in clinical management.

One cannot ignore the broader implications of refining neuroprognostication tools that can accurately assess the severity and trajectory of encephalopathy. Beyond clinical decision-making, this could profoundly affect counseling for families, resource allocation, and the design of clinical trials for novel neuroprotective agents. The promise of a neuroimaging marker that reliably bridges brain microstructure with functional outcomes could revolutionize neonatal neurology by transforming unpredictable prognoses into data-driven forecasts.

Despite these promising aspects, the authors emphasize that diffusion kurtosis imaging is not a panacea. Its current sensitivity and specificity, while superior to conventional diffusion imaging in some domains, do not yet completely resolve the heterogeneity inherent in neonatal encephalopathy outcomes. There remain cases where kurtosis measures produce ambiguous results, mandating multimodal approaches that integrate clinical, electrophysiological, and metabolic data for comprehensive evaluation. The authors advocate for a future where DKI complements rather than replaces existing diagnostic frameworks.

Technological advancements are anticipated to alleviate some issues related to DKI implementation. Developments in rapid acquisition sequences, motion correction algorithms, and artificial intelligence-driven image processing hold potential to streamline and democratize the use of kurtosis imaging. Such innovations could shorten imaging times, enhance resolution, and reduce interpretive subjectivity, making DKI feasible even in less specialized centers. These advances will be pivotal if diffusion kurtosis imaging is to transcend research settings and fulfill its promise in neonatal care.

Another emerging horizon involves integrating DKI with other advanced neuroimaging modalities, such as functional MRI and spectroscopy. Multimodal imaging has shown superior prognostic precision by providing complementary information on brain metabolism, connectivity, and structure. The synergistic use of these techniques could construct a multidimensional framework for assessing neonatal brain injury, surpassing the granularity offered by any single modality alone. The study by Lewis et al. hints at this integrative future by situating DKI within broader neuroimaging innovations.

While this research marks a decisive stride towards enhancing neuroprognostication in neonatal encephalopathy, it simultaneously highlights the importance of longitudinal studies involving larger cohorts. Validation across diverse populations and clinical settings is essential to establish normative kurtosis values and diagnostic thresholds, enabling robust translation into clinical practice. Additionally, harmonizing imaging protocols internationally will facilitate comparative studies and foster consensus on best practices for DKI application in neonatology.

Ethical considerations also emerge when implementing advanced prognostic technologies. The ability to predict neurological outcomes with increasing accuracy raises questions about decision-making in critical care, parental counseling, and potential biases in treatment allocation. Hence, alongside technological progress, frameworks ensuring compassionate communication and equitable care delivery must evolve in tandem. The nuanced prognostic data provided by DKI necessitate thoughtful clinical integration to truly benefit afflicted infants and their families.

In conclusion, diffusion kurtosis imaging stands at the nexus of neuroimaging innovation and neonatal clinical application. The work by Lewis, Kalish, and Cizmeci encapsulates an inspiring trajectory towards more precise, biologically grounded prognostication in the challenging landscape of neonatal encephalopathy. Although facing notable practical and interpretive limitations, DKI advances our ability to peer into the infant brain’s microarchitecture, promising transformative impacts on early diagnosis, treatment stratification, and ultimate neurodevelopmental outcomes. The journey from research to bedside application will demand continued interdisciplinary collaboration, technological refinement, and ethical vigilance but holds profound potential to change neonatal neurology forever.

Subject of Research: Neuroprognostication in neonatal encephalopathy using diffusion kurtosis imaging

Article Title: Advancing neuroprognostication in neonatal encephalopathy: promise and limitations of diffusion kurtosis imaging

Article References: Lewis, J.D., Kalish, B.T. & Cizmeci, M.N. Advancing neuroprognostication in neonatal encephalopathy: promise and limitations of diffusion kurtosis imaging. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04714-6

Image Credits: AI Generated

DOI: 15 December 2025

PWML, characterized by small, focal abnormalities detectable on MRI within the cerebral white matter, have historically been regarded with some ambiguity in their clinical significance. These lesions appear as discrete hyperintensities on T1-weighted images and hypointensities on T2-weighted sequences, scattered throughout delicate white matter tracts. Their pathophysiology is believed to stem from microvascular disruption and localized glial injury due to the relative fragility of the immature cerebral vasculature in preterm neonates between 24 and 32 weeks of gestational age. Until now, the association between PWML and long-term neurodevelopmental deficits, including motor impairment, had been suggested but remained inconclusive.

The compelling findings from the latest study definitively correlate the presence and distribution of PWML with an increased risk of cerebral palsy, a lifelong movement disorder resulting from early brain injury. Pediatric neurologists have long sought reliable prognostic markers that could facilitate early intervention and supportive therapy to mitigate the devastating sequelae of cerebral palsy. By utilizing advanced neuroimaging protocols combined with rigorous longitudinal clinical follow-up, clinicians now have tangible evidence that routine brain MRI in preterm infants can provide critical prognostic information beyond conventional cranial ultrasound.

The implications of integrating routine MRI scanning into neonatal intensive care units (NICUs) are profound. Unlike ultrasound, which often fails to detect the subtle white matter abnormalities characteristic of PWML, MRI offers unparalleled spatial resolution and tissue contrast, enabling the visualization of these minute lesions. Early identification of infants harboring PWML could lead to targeted neuroprotective strategies, including optimized respiratory support, neurorehabilitation, and potentially pharmacologic interventions aimed at minimizing secondary neuronal injury.

Importantly, this research leverages a multidisciplinary approach utilizing neuroradiology, neonatal neurology, and developmental pediatrics to build a robust correlation between lesion burden, lesion location, and subsequent motor outcome severity. Lesions localized to periventricular and subcortical regions, areas subserved by critical motor pathways, were especially predictive of later diagnosis of spastic diplegia, one of the most common clinical manifestations of cerebral palsy in prematurity. The stratification of lesion topography offers a nuanced predictive model previously unavailable in neonatal neuroimaging practice.

From a technical standpoint, the study deployed advanced MRI sequences, including diffusion-weighted imaging (DWI) and susceptibility-weighted imaging (SWI), to enhance lesion detectability. DWI is sensitive to cytotoxic edema, often preceding irreversible tissue damage, while SWI highlights microhemorrhages that often accompany PWML. These modalities, combined with refined segmentation algorithms, allowed for quantification of lesion volume and mapping onto white matter tracts, correlating structural abnormalities with neurofunctional outcomes.

Beyond clinical practice, this new understanding of PWML contributes to the fundamental neuroscience of prematurity-related brain injury. It supports the hypothesis that cerebral white matter damage, a hallmark of encephalopathy of prematurity, encompasses a spectrum wherein punctate lesions represent focal ischemic insults. These, in turn, disrupt oligodendrocyte maturation and myelination, critical processes during late gestation brain development. The interplay between vascular insult and glial vulnerability elucidated by this work deepens our grasp of the pathobiology underpinning cerebral palsy.

While the study unequivocally supports the inclusion of routine MRI in the clinical evaluation of preterm infants, logistical and economic challenges must be addressed. MRI requires specialized equipment and sedation protocols that pose risks and limitations in the fragile neonatal population. Nevertheless, advances in quiet, motion-robust imaging technologies and rapid sequence acquisitions are making bedside-compatible neonatal MRI a realistic goal. Health systems must consider these investments justified given the potential long-term cost savings by enabling earlier, individualized therapeutic interventions.

From a public health perspective, this research has the potential to transform neonatal care paradigms globally. Standardized neuroimaging protocols including routine MRI could become part of evidence-based guidelines, fostering equitable access to high-quality diagnostic evaluation for at-risk infants. Early detection would also empower families and caregivers with prognostic clarity and facilitate enrollment in early intervention programs that improve neurodevelopmental trajectories.

The impact of this research may ripple into future therapeutic trials, informing inclusion criteria and serving as an objective biomarker for treatment response. For example, neuroprotective agents targeting inflammation and oxidative stress pathways could be stratified based on lesion presence and severity, refining precision medicine approaches in neonatal neurology. Moreover, PWML quantification and localization may serve as surrogate endpoints, accelerating the pace of clinical innovation.

Importantly, this landmark study highlights the indispensable role of longitudinal follow-up in correlating imaging findings with clinical outcomes. Multidisciplinary teams performed serial developmental assessments extending into early childhood, ensuring that MRI markers are not only cross-sectional snapshots but predictive tools of functional prognosis. This comprehensive approach sets a new standard in neonatal neurocritical care research.

Ethical considerations also emerge from the implementation of routine MRI screening, including informed consent, the psychological impact of early risk notification on families, and managing incidental findings unrelated to cerebral palsy risk. Neonatal care providers will need training to navigate these complex conversations compassionately while maintaining transparency and evidence-based counseling.

Looking ahead, integration of artificial intelligence and machine learning algorithms promises to enhance the sensitivity and specificity of PWML detection. Automated lesion segmentation and risk modeling could reduce diagnostic variability and augment clinical decision-making. The convergence of big data analytics with neonatal neuroimaging heralds an exciting era of personalized neurodevelopmental care.

In conclusion, the identification of punctate white matter lesions as potent predictors of cerebral palsy risk marks a significant advancement in neonatal neurology. This breakthrough not only challenges existing screening paradigms but also opens new horizons for early intervention and improved outcomes for the most vulnerable infants. As research continues to dissect the complexities of prematurity-related brain injury, routine brain MRI stands out as an indispensable tool — a lens into the developing brain that promises hope amidst uncertainty.

Subject of Research: Prediction of cerebral palsy risk in preterm infants through detection of punctate white matter lesions via routine brain MRI.

Article Title: Punctate white matter lesions predict risk for cerebral palsy: further evidence for routine brain MRI in preterm infants.

Article References:
Selvanathan, T., Gano, D. Punctate white matter lesions predict risk for cerebral palsy: further evidence for routine brain MRI in preterm infants. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04333-1

Image Credits: AI Generated